Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Pieris Pharmaceuticals stock

Learn how to easily invest in Pieris Pharmaceuticals stock.

Pieris Pharmaceuticals Inc is a biotechnology business based in the US. Pieris Pharmaceuticals shares (PIRS) are listed on the NASDAQ and all prices are listed in US Dollars. Pieris Pharmaceuticals employs 124 staff and has a trailing 12-month revenue of around $27.2 million.

How to buy shares in Pieris Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PIRS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Pieris Pharmaceuticals stock price (NASDAQ: PIRS)

Use our graph to track the performance of PIRS stocks over time.

Pieris Pharmaceuticals shares at a glance

Information last updated 2022-09-26.
Latest market close$1.15
52-week range$1.14 - $5.52
50-day moving average $1.59
200-day moving average $2.51
Wall St. target price$7.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.68

Buy Pieris Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pieris Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pieris Pharmaceuticals price performance over time

Historical closes compared with the close of $1.15 from 2022-09-29

1 week (2022-09-23) -5.74%
1 month (2022-08-30) -21.77%
3 months (2022-06-30) -38.50%
6 months (2022-03-30) -62.42%
1 year (2021-09-30) -77.76%
2 years (2020-09-30) -44.44%
3 years (2019-09-30) 3.41
5 years (2017-09-29) 5.76

Pieris Pharmaceuticals financials

Revenue TTM $27.2 million
Gross profit TTM $-35,238,000
Return on assets TTM -23.11%
Return on equity TTM -91.14%
Profit margin -152.68%
Book value $0.60
Market capitalisation $86.3 million

TTM: trailing 12 months

Pieris Pharmaceuticals share dividends

We're not expecting Pieris Pharmaceuticals to pay a dividend over the next 12 months.

Have Pieris Pharmaceuticals's shares ever split?

Pieris Pharmaceuticals's shares were split on a 25:11 basis on 7 December 2014. So if you had owned 11 shares the day before before the split, the next day you'd have owned 25 shares. This wouldn't directly have changed the overall worth of your Pieris Pharmaceuticals shares – just the quantity. However, indirectly, the new 56% lower share price could have impacted the market appetite for Pieris Pharmaceuticals shares which in turn could have impacted Pieris Pharmaceuticals's share price.

Pieris Pharmaceuticals share price volatility

Over the last 12 months, Pieris Pharmaceuticals's shares have ranged in value from as little as $1.14 up to $5.52. A popular way to gauge a stock's volatility is its "beta".

PIRS.US volatility(beta: 1.05)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pieris Pharmaceuticals's is 1.0535. This would suggest that Pieris Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Pieris Pharmaceuticals overview

Pieris Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc. ; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc.

Frequently asked questions

What percentage of Pieris Pharmaceuticals is owned by insiders or institutions?
Currently 9.861% of Pieris Pharmaceuticals shares are held by insiders and 58.783% by institutions.
How many people work for Pieris Pharmaceuticals?
Latest data suggests 124 work at Pieris Pharmaceuticals.
When does the fiscal year end for Pieris Pharmaceuticals?
Pieris Pharmaceuticals's fiscal year ends in December.
Where is Pieris Pharmaceuticals based?
Pieris Pharmaceuticals's address is: 255 State Street, Boston, MA, United States, 02109
What is Pieris Pharmaceuticals's ISIN number?
Pieris Pharmaceuticals's international securities identification number is: US7207951036
What is Pieris Pharmaceuticals's CUSIP number?
Pieris Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 720795103

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site